Cost-Effectiveness of Switching to the Nonavale...

By Rene Pretorius

January 13, 2025

A recent study on the cost-effectiveness of transitioning from the bivalent human papillomavirus vaccine (2vHPV) to the nonavalent vacci...
Advancing Newborn Screening for Sickle Cell Disease in Africa
Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate
Improving Access to Trikafta for Cystic Fibrosis Patients in South Africa
Egypt’s Hepatitis C Program: A Model for Africa’s Health Initiatives
Maturity Level 3 in Medicines Regulation in Senegal and Rwanda
Infection Control and Disease Surveillance in Africa
CMS Price Negotiations: Bridging the Gap in US Drug Pricing
Access to Anti-Obesity Medication for Medicare and Medicaid
Canada’s Drug Agency Launches Consultation on New Methods Guide for Hea...
Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Pract...
Addressing Physical Inactivity in MENA and Beyond
Smartening Africa’s Drug Supply Chain with IBM AI